Genflow Biosciences PLC Launches New Development Program
Genflow Biosciences (LSE:GENF)(OTCQB:GENFF), Europe's only public longevity company, has announced a new ophthalmology development program focusing on novel gene therapy using their proprietary Centenarian SIRT6 (cSIRT6) technology.
The program will utilize a specially designed non-viral vector for precise delivery of SIRT6 to the eye, targeting ocular conditions including corneal pathologies and glaucoma. The company has signed a Material Transfer Agreement (MTA) with a leading ophthalmology company to collaborate on the design and development of the eye-targeted cSIRT6 non-viral vector.
According to CEO Dr. Eric Leire, the eye's closed and accessible compartment makes it an ideal target for gene therapy, with SIRT6 showing promising potential in treating corneal endothelial disorders and glaucoma.
Genflow Biosciences (LSE:GENF)(OTCQB:GENFF), l'unica azienda pubblica europea dedicata alla longevità, ha annunciato un nuovo programma di sviluppo in oftalmologia incentrato su una terapia genica innovativa utilizzando la loro tecnologia proprietaria Centenarian SIRT6 (cSIRT6).
Il programma utilizzerà un vettore non virale appositamente progettato per la consegna precisa di SIRT6 all'occhio, mirando a condizioni oculari tra cui patologie corneali e glaucoma. L'azienda ha firmato un Accordo di Trasferimento Materiale (MTA) con una rinomata azienda oftalmologica per collaborare nella progettazione e nello sviluppo del vettore non virale cSIRT6 mirato all'occhio.
Secondo il CEO Dr. Eric Leire, la chiusura e l'accessibilità dell'occhio lo rendono un obiettivo ideale per la terapia genica, con SIRT6 che mostra un potenziale promettente nel trattamento dei disturbi endoteliali corneali e del glaucoma.
Genflow Biosciences (LSE:GENF)(OTCQB:GENFF), la única empresa pública de longevidad en Europa, ha anunciado un nuevo programa de desarrollo en oftalmología centrado en una terapia génica innovadora utilizando su tecnología propietaria Centenarian SIRT6 (cSIRT6).
El programa utilizará un vector no viral diseñado específicamente para la entrega precisa de SIRT6 al ojo, enfocándose en condiciones oculares que incluyen patologías corneales y glaucoma. La empresa ha firmado un Acuerdo de Transferencia de Material (MTA) con una empresa de oftalmología líder para colaborar en el diseño y desarrollo del vector no viral cSIRT6 dirigido al ojo.
Según el CEO Dr. Eric Leire, el compartimento cerrado y accesible del ojo lo convierte en un objetivo ideal para la terapia génica, con SIRT6 mostrando un potencial prometedor en el tratamiento de trastornos endoteliales corneales y glaucoma.
Genflow Biosciences (LSE:GENF)(OTCQB:GENFF), 유럽 유일의 상장 장수 기업,이 새로운 안과 개발 프로그램을 발표했습니다. 이 프로그램은 그들의 독점 기술 Centenarian SIRT6 (cSIRT6)를 사용한 혁신적인 유전자 치료에 중점을 두고 있습니다.
이 프로그램은 SIRT6를 눈에 정밀하게 전달하기 위해 특별히 설계된 비바이러스 벡터를 사용할 것이며, 각막 병리 및 녹내장을 포함한 안과 질환을 목표로 합니다. 이 회사는 눈을 겨냥한 cSIRT6 비바이러스 벡터의 설계 및 개발을 위해 선도적인 안과 회사와 물질 이전 계약 (MTA)를 체결했습니다.
CEO인 Eric Leire 박사에 따르면, 눈의 닫힌 접근 가능한 구획은 유전자 치료의 이상적인 목표로 만들며, SIRT6는 각막 내피 장애 및 녹내장 치료에 유망한 잠재력을 보여줍니다.
Genflow Biosciences (LSE:GENF)(OTCQB:GENFF), la seule entreprise publique de longévité en Europe, a annoncé un nouveau programme de développement en ophtalmologie axé sur une thérapie génique novatrice utilisant leur technologie propriétaire Centenarian SIRT6 (cSIRT6).
Le programme utilisera un vecteur non viral spécialement conçu pour la livraison précise de SIRT6 à l'œil, ciblant des conditions oculaires telles que les pathologies cornéennes et le glaucome. L'entreprise a signé un Accord de Transfert de Matériel (MTA) avec une entreprise ophtalmologique de premier plan pour collaborer à la conception et au développement du vecteur non viral cSIRT6 ciblé sur l'œil.
Selon le PDG Dr. Eric Leire, le compartiment fermé et accessible de l'œil en fait une cible idéale pour la thérapie génique, SIRT6 montrant un potentiel prometteur dans le traitement des troubles endothéliaux cornéens et du glaucome.
Genflow Biosciences (LSE:GENF)(OTCQB:GENFF), das einzige öffentliche Unternehmen für Langlebigkeit in Europa, hat ein neues Entwicklungsprogramm in der Augenheilkunde angekündigt, das sich auf neuartige Gentherapien mit ihrer proprietären Technologie Centenarian SIRT6 (cSIRT6) konzentriert.
Das Programm wird einen speziell entwickelten nicht-viralen Vektor zur präzisen Lieferung von SIRT6 ins Auge nutzen und zielt auf Augenkrankheiten wie Hornhauterkrankungen und Glaukom ab. Das Unternehmen hat eine Material Transfer Agreement (MTA) mit einem führenden Augenheilkundeunternehmen unterzeichnet, um bei der Gestaltung und Entwicklung des augenzielgerichteten cSIRT6 nicht-viralen Vektors zusammenzuarbeiten.
Laut CEO Dr. Eric Leire macht das geschlossene und zugängliche Kompartiment des Auges es zu einem idealen Ziel für Gentherapien, wobei SIRT6 vielversprechendes Potenzial bei der Behandlung von Hornhautendothelerkrankungen und Glaukom zeigt.
- None.
- None.
Genflow Biosciences Launches New Ophthalmology Development Program
Signs MTA with Leading Ophthalmology Company
LONDON, UK / ACCESS Newswire / April 10, 2025 / Genflow Biosciences Plc (LSE:GENF)(OTCQB:GENFF) ("Genflow" or "the Company"), the only publicly listed longevity company in Europe, is excited to announce the launch of a new development program in ophthalmology, focused on advancing a novel gene therapy leveraging its proprietary Centenarian SIRT6 (cSIRT6). This therapy will utilize a specially designed non-viral vector engineered for precise delivery of Genflow's SIRT6 to the eye. The therapy is designed to combat ocular problems including several pathologies of the cornea and glaucoma.
This initiative is part of Genflow's continued efforts to optimize its gene therapy and proprietary Centenarian SIRT6. As part of this effort, Genflow has signed a Material Transfer Agreement (MTA) with a leading ophthalmology company, to collaborate on the design and development of the eye-targeted cSIRT6 non-viral vector to target ocular diseases. These therapies will leverage Genflow's proprietary SIRT6 Centenarian gene technology, in combination with an advanced vector delivery system.
Said Dr. Eric Leire, CEO of Genflow Biosciences: "We are thrilled to advance our ophthalmology program. The eye, as a closed and accessible compartment, presents an ideal target for gene therapy. More importantly, we believe that SIRT6 holds significant promise to transform the treatment landscape for corneal endothelial disorders and glaucoma."
Contacts
Genflow Biosciences | Harbor Access |
Dr Eric Leire, CEO | Jonathan Paterson, Investor Relations |
+32-477-495-881 | +1 475 477 9401 |
|
Corporate Brokers |
|
Capital Plus Partners Ltd |
|
Jon Critchley, +44 0203 821 6168 |
|
About Genflow Biosciences
Founded in 2020, Genflow Biosciences Plc. (LSE:GENF)(OTCQB:GENFF), a biotechnology company headquartered in the UK with R&D facilities in Belgium, is pioneering gene therapies to decelerate the aging process, with the goal of promoting longer and healthier lives while mitigating the financial, emotional, and social impacts of a fast-growing aging global population. Genflow's lead compound, GF-1002, works through the delivery of a centenarian variant of the SIRT6 gene which has yielded promising preclinical results. Genflow's 12-month proof-of-concept clinical trial evaluating their SIRT6-centenarian gene therapy in aged dogs began in March 2025. Other programs planned for 2025, include a clinical trial that will explore the potential benefits of GF-1002 in treating MASH (Metabolic Dysfunction-Associated Steatohepatitis), the most prevalent chronic liver disease for which there is no effective treatments. Please visit www.genflowbio.com and follow the Company on LinkedIn and X.
This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
SOURCE: Genflow Biosciences PLC
View the original press release on ACCESS Newswire
FAQ
What is the new development program announced by Genflow Biosciences (GENFF) in April 2025?
How will Genflow's GENFF ophthalmology program deliver the SIRT6 therapy to the eye?
What partnership did Genflow Biosciences (GENFF) secure for their ophthalmology program?
What specific eye conditions will Genflow's GENFF SIRT6 therapy target?
Why did Genflow Biosciences (GENFF) choose to focus on eye treatments for their SIRT6 therapy?
